First Financial Corp IN Acquires 214 Shares of Amgen Inc. (NASDAQ:AMGN)

First Financial Corp IN lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 65.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 539 shares of the medical research company’s stock after acquiring an additional 214 shares during the period. First Financial Corp IN’s holdings in Amgen were worth $140,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the company. PFW Advisors LLC acquired a new stake in Amgen in the 4th quarter valued at $1,105,000. Miracle Mile Advisors LLC increased its position in shares of Amgen by 3.0% in the fourth quarter. Miracle Mile Advisors LLC now owns 6,016 shares of the medical research company’s stock valued at $1,568,000 after acquiring an additional 176 shares during the last quarter. Horizon Wealth Management LLC raised its holdings in Amgen by 13.3% during the fourth quarter. Horizon Wealth Management LLC now owns 1,217 shares of the medical research company’s stock worth $317,000 after acquiring an additional 143 shares in the last quarter. Burns J W & Co. Inc. NY boosted its position in Amgen by 0.5% during the fourth quarter. Burns J W & Co. Inc. NY now owns 22,349 shares of the medical research company’s stock valued at $5,825,000 after purchasing an additional 117 shares during the last quarter. Finally, Elevated Capital Advisors LLC grew its stake in Amgen by 8.1% in the fourth quarter. Elevated Capital Advisors LLC now owns 1,664 shares of the medical research company’s stock valued at $434,000 after purchasing an additional 125 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 3.0 %

AMGN stock opened at $270.19 on Tuesday. The company has a market cap of $145.24 billion, a PE ratio of 34.60, a price-to-earnings-growth ratio of 2.91 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The business has a 50-day simple moving average of $278.16 and a 200 day simple moving average of $308.35.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the company earned $4.96 EPS. Sell-side analysts anticipate that Amgen Inc. will post 19.53 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.52%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is currently 121.90%.

Analyst Ratings Changes

Several equities research analysts have recently commented on AMGN shares. Royal Bank of Canada cut their price objective on Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a report on Wednesday, November 27th. Barclays lifted their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Piper Sandler dropped their target price on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, Wolfe Research began coverage on Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus price target of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.